115 related articles for article (PubMed ID: 28419717)
1. Ligand recognition properties of the vasopressin V2 receptor studied under QSAR and molecular modeling strategies.
Martínez-Archundia M; Colín-Astudillo B; Moreno-Vargas LM; Ramírez-Galicia G; Garduño-Juárez R; Deeb O; Contreras-Romo MC; Quintanar-Stephano A; Abarca-Rojano E; Correa-Basurto J
Chem Biol Drug Des; 2017 Nov; 90(5):840-853. PubMed ID: 28419717
[TBL] [Abstract][Full Text] [Related]
2. Exploring the ligand recognition properties of the human vasopressin V1a receptor using QSAR and molecular modeling studies.
Contreras-Romo MC; Martínez-Archundia M; Deeb O; Slusarz MJ; Ramírez-Salinas G; Garduño-Juárez R; Quintanar-Stephano A; Ramírez-Galicia G; Correa-Basurto J
Chem Biol Drug Des; 2014 Feb; 83(2):207-23. PubMed ID: 24010681
[TBL] [Abstract][Full Text] [Related]
3. Prediction of molecular interactions and physicochemical properties relevant for vasopressin V2 receptor antagonism.
de la Nuez Veulens A; Ginarte YMÁ; Fernandez RER; Leclerc F; Cabrera LAM
J Mol Model; 2022 Jan; 28(2):31. PubMed ID: 34997307
[TBL] [Abstract][Full Text] [Related]
4. A Three-Site Mechanism for Agonist/Antagonist Selective Binding to Vasopressin Receptors.
Saleh N; Saladino G; Gervasio FL; Haensele E; Banting L; Whitley DC; Sopkova-de Oliveira Santos J; Bureau R; Clark T
Angew Chem Int Ed Engl; 2016 Jul; 55(28):8008-12. PubMed ID: 27184628
[TBL] [Abstract][Full Text] [Related]
5. Long Residence Time at the Vasopressin V
Zhang H; Yan W; Sun Y; Yuan H; Su L; Cao X; Wang P; Xu Z; Hu Y; Wang Z; Wang Y; Fu K; Sun Y; Chen Y; Cheng J; Guo D
J Med Chem; 2022 Jun; 65(11):7717-7728. PubMed ID: 35363466
[TBL] [Abstract][Full Text] [Related]
6. Vasopressin V1a and V1b receptor modulators: a patent review (2012 - 2014).
Ślusarz MJ
Expert Opin Ther Pat; 2015 Jun; 25(6):711-22. PubMed ID: 25776143
[TBL] [Abstract][Full Text] [Related]
7. Investigation of mechanism of desmopressin binding in vasopressin V2 receptor versus vasopressin V1a and oxytocin receptors: molecular dynamics simulation of the agonist-bound state in the membrane-aqueous system.
Slusarz MJ; Slusarz R; Ciarkowski J
Biopolymers; 2006 Apr; 81(5):321-38. PubMed ID: 16333859
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling of histamine H3 receptor and QSAR studies on arylbenzofuran derived H3 antagonists.
Dastmalchi S; Hamzeh-Mivehroud M; Ghafourian T; Hamzeiy H
J Mol Graph Model; 2008 Jan; 26(5):834-44. PubMed ID: 17561422
[TBL] [Abstract][Full Text] [Related]
9. Molecular modelling of the vasopressin V2 receptor/antagonist interactions.
Czaplewski C; Kaźmierkiewicz R; Ciarkowski J
Acta Biochim Pol; 1998; 45(1):19-26. PubMed ID: 9701492
[TBL] [Abstract][Full Text] [Related]
10. Tolvaptan-Type Vasopressin Receptor Ligands: Important Role of Axial Chirality in the Active Form.
Tabata H; Yoneda T; Oshitari T; Takahashi H; Natsugari H
J Med Chem; 2017 May; 60(10):4503-4509. PubMed ID: 28475329
[TBL] [Abstract][Full Text] [Related]
11. The physiological and pathophysiological functions of renal and extrarenal vasopressin V2 receptors.
Juul KV; Bichet DG; Nielsen S; Nørgaard JP
Am J Physiol Renal Physiol; 2014 May; 306(9):F931-40. PubMed ID: 24598801
[TBL] [Abstract][Full Text] [Related]
12. Analysis of interactions responsible for vasopressin binding to human neurohypophyseal hormone receptors-molecular dynamics study of the activated receptor-vasopressin-G(alpha) systems.
Slusarz MJ; Giełdoń A; Slusarz R; Ciarkowski J
J Pept Sci; 2006 Mar; 12(3):180-9. PubMed ID: 16114100
[TBL] [Abstract][Full Text] [Related]
13. Identification of avian vasotocin receptor subtype-specific antagonists involved in the stress response of the chicken, Gallus gallus.
Kang SW; Jayanthi S; Nagarajan G; Suresh Kumar TK; Kuenzel WJ
J Biomol Struct Dyn; 2019 Apr; 37(7):1685-1699. PubMed ID: 29658387
[TBL] [Abstract][Full Text] [Related]
14. Vasopressin receptors and pharmacological chaperones: from functional rescue to promising therapeutic strategies.
Mouillac B; Mendre C
Pharmacol Res; 2014 May; 83():74-8. PubMed ID: 24239889
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoperone rescue of vasopressin 2 receptor mutants reveals unexpected constitutive activity and coupling bias.
Janovick JA; Spicer TP; Bannister TD; Scampavia L; Conn PM
PLoS One; 2017; 12(8):e0181830. PubMed ID: 28767678
[TBL] [Abstract][Full Text] [Related]
16. Stepwise development of structure-activity relationship of diverse PARP-1 inhibitors through comparative and validated in silico modeling techniques and molecular dynamics simulation.
Halder AK; Saha A; Saha KD; Jha T
J Biomol Struct Dyn; 2015; 33(8):1756-79. PubMed ID: 25350685
[TBL] [Abstract][Full Text] [Related]
17. Structure-Affinity and Structure-Kinetic Relationship Studies of Benzodiazepine Derivatives for the Development of Efficacious Vasopressin V
Cao X; Wang P; Zhao W; Yuan H; Hu H; Chen T; Zhang Y; Ren Y; Su L; Fu K; Liu H; Guo D
J Med Chem; 2023 Mar; 66(5):3621-3634. PubMed ID: 36732931
[TBL] [Abstract][Full Text] [Related]
18. Molecular modeling of the human vasopressin V2 receptor/agonist complex.
Czaplewski C; Kaźmierkiewicz R; Ciarkowski J
J Comput Aided Mol Des; 1998 May; 12(3):275-87. PubMed ID: 9749370
[TBL] [Abstract][Full Text] [Related]
19. In silico exploration of c-KIT inhibitors by pharmaco-informatics methodology: pharmacophore modeling, 3D QSAR, docking studies, and virtual screening.
Chaudhari P; Bari S
Mol Divers; 2016 Feb; 20(1):41-53. PubMed ID: 26416560
[TBL] [Abstract][Full Text] [Related]
20. How good are ensembles in improving QSAR models? The case with eCoRIA.
Khedkar VM; Joseph J; Pissurlenkar R; Saran A; Coutinho EC
J Biomol Struct Dyn; 2015; 33(4):749-69. PubMed ID: 24754910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
